

## Literaturverzeichnis

**Thema:** Chronische Trockenheit, chronische Leiden? – Das Sjögren-Syndrom im Fokus

**Autorin:** Nirina Götze, Claudia Sachse, Helena Bächer, Anna-Karina Maier, Susanne Nahles

---

1. Fox RI. Sjogren's syndrome. *Lancet*. 2005;366(9482):321–31.
2. Negrini S, Emmi G, Greco M, Borro M, Sardanelli F, Murdaca G, et al. Sjogren's syndrome: a systemic autoimmune disease. *Clin Exp Med*. 2022;22(1):9–25.
3. Romao VC, Talarico R, Scire CA, Vieira A, Alexander T, Baldini C, et al. Sjogren's syndrome: state of the art on clinical practice guidelines. *RMD Open*. 2018;4(Suppl 1):e000789.
4. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjogren's syndrome. *Autoimmun Rev*. 2010;9(5):A305–10.
5. Brito-Zeron P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. Sjogren syndrome. *Nat Rev Dis Primers*. 2016;2:16047.
6. Mariette X, Criswell LA. Primary Sjogren's Syndrome. *N Engl J Med*. 2018;378(10):931–9.
7. Thurtle E, Grosjean A, Steenackers M, Strege K, Barcelos G, Goswami P. Epidemiology of Sjogren's: A Systematic Literature Review. *Rheumatol Ther*. 2024;11(1):1–17.
8. Parisi S, Lo Sardo L, Ditto MC, Gnani R, Dalmaso M, Migliardi A, et al. Pos0998-Hpr the Epidemiology of Primary Sjogren's Syndrome: Is It a Rare Disease? *Annals of the Rheumatic Diseases*. 2023;82.
9. Westhoff G, Zink A. [Epidemiology of primary Sjogren's syndrome]. *Z Rheumatol*. 2010;69(1):41–9.
10. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. *Arch Intern Med*. 2004;164(12):1275–84.
11. Bowman SJ. Patient-reported outcomes including fatigue in primary Sjogren's syndrome. *Rheum Dis Clin North Am*. 2008;34(4):949–62, ix.
12. Komori K, Komori M, Horino T, Nishiyama S, Takei M, Suganuma N. Factors associated with delayed diagnosis of Sjogren's syndrome among members of the Japanese Sjogren's Association for Patients. *Clin Exp Rheumatol*. 2021;39 Suppl 133(6):146–52.
13. Ng WF, Bowman SJ, Griffiths B, group Us. United Kingdom Primary Sjogren's Syndrome Registry--a united effort to tackle an orphan rheumatic disease. *Rheumatology (Oxford)*. 2011;50(1):32–9.
14. Meinecke A, Kreis K, Olson P, Hoepfer JR, Ernst D, Hoepfer K, et al. Ab0840 Association of a Diagnostic Delay and Poor General Health Status and General Performance in Primary Sjögren's Syndrome: A Cross-Sectional Study. *Annals of the Rheumatic Diseases*. 2024;83:1717–8.
15. Markusse HM, Oudkerk M, Vroom TM, Breedveld FC. Primary Sjogren's syndrome: clinical spectrum and mode of presentation based on an analysis of 50 patients selected from a department of rheumatology. *Neth J Med*. 1992;40(3-4):125–34.
16. Meinecke A, Kreis K, Olson P, Hoepfer JR, Engelke F, Seeliger T, et al. Impact of time to diagnosis in patients with primary Sjogren's syndrome: a cross-sectional study. *Clin Exp Rheumatol*. 2024;42(12):2444–52.

17. Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary Sjogren's syndrome: a systematic review and meta-analysis. *Ann Rheum Dis*. 2015;74(11):1983–9.
18. Whitacre CC. Sex differences in autoimmune disease. *Nat Immunol*. 2001;2(9):777–80.
19. Ostuni PA, Ianniello A, Sfriso P, Mazzola G, Andretta M, Gambari PF. Juvenile onset of primary Sjogren's syndrome: report of 10 cases. *Clin Exp Rheumatol*. 1996;14(6):689–93.
20. Witte T. [Sjogren's syndrome]. *Z Rheumatol*. 2019;78(6):511–7.
21. Smolik J, Taylor R, Wilson V, Weber M, Hasan I, Harrison E, et al. Literature review: the prevalence and indicators of sjögren's syndrome in juveniles. *Oral Health and Care*. 2017;2(2).
22. Stefanski AL, Tomiak C, Pleyer U, Dietrich T, Burmester GR, Dorner T. The Diagnosis and Treatment of Sjogren's Syndrome. *Dtsch Arztebl Int*. 2017;114(20):354–61.
23. Pasoto SG, Adriano de Oliveira Martins V, Bonfa E. Sjogren's syndrome and systemic lupus erythematosus: links and risks. *Open Access Rheumatol*. 2019;11:33–45.
24. Hernandez-Molina G, Avila-Casado C, Cardenas-Velazquez F, Hernandez-Hernandez C, Calderillo ML, Marroquin V, et al. Similarities and differences between primary and secondary Sjogren's syndrome. *J Rheumatol*. 2010;37(4):800–8.
25. Miyamoto ST, Valim V, Fisher BA. Health-related quality of life and costs in Sjogren's syndrome. *Rheumatology (Oxford)*. 2021;60(6):2588–601.
26. Bolstad AI, Skarstein K. Epidemiology of Sjogren's Syndrome—from an Oral Perspective. *Curr Oral Health Rep*. 2016;3(4):328–36.
27. al-Hashimi I. The management of Sjogren's syndrome in dental practice. *J Am Dent Assoc*. 2001;132(10):1409–17; quiz 60–1.
28. Fye KH, Terasaki PI, Moutsopoulos H, Daniels TE, Michalski JP, Talal N. Association of Sjogren's syndrome with HLA-B8. *Arthritis Rheum*. 1976;19(5):883–6.
29. Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjogren's syndrome. *J Autoimmun*. 2010;35(3):225–31.
30. Witte T. [Pathogenesis and diagnosis of Sjogren's syndrome]. *Z Rheumatol*. 2010;69(1):50–6.
31. Sandhya P, Kurien BT, Danda D, Scofield RH. Update on Pathogenesis of Sjogren's Syndrome. *Curr Rheumatol Rev*. 2017;13(1):5–22.
32. Mavragani CP, Moutsopoulos HM. Sjogren syndrome. *CMAJ*. 2014;186(15):E579–86.
33. Manoussakis MN, Kapsogeorgou EK. The role of epithelial cells in the pathogenesis of Sjogren's syndrome. *Clin Rev Allergy Immunol*. 2007;32(3):225–30.
34. Hall JC, Baer AN, Shah AA, Criswell LA, Shiboski CH, Rosen A, et al. Molecular Subsetting of Interferon Pathways in Sjogren's Syndrome. *Arthritis Rheumatol*. 2015;67(9):2437–46.
35. Nezos A, Mavragani CP. Contribution of Genetic Factors to Sjogren's Syndrome and Sjogren's Syndrome Related Lymphomagenesis. *J Immunol Res*. 2015;2015:754825.
36. Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. *Arthritis Rheum*. 2005;52(4):1185–95.
37. Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjogren syndrome. *Nat Rev Rheumatol*. 2018;14(3):133–45.
38. Verstappen GM, Kroese FGM, Bootsma H. T cells in primary Sjogren's syndrome: targets for early intervention. *Rheumatology (Oxford)*. 2021;60(7):3088–98.

39. Bombardieri M, Barone F, Humby F, Kelly S, McGurk M, Morgan P, et al. Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjogren's syndrome. *J Immunol*. 2007;179(7):4929–38.
40. Brito-Zeron P, Kostov B, Fraile G, Caravia-Duran D, Maure B, Rascon FJ, et al. Characterization and risk estimate of cancer in patients with primary Sjogren syndrome. *J Hematol Oncol*. 2017;10(1):90.
41. Ernst D, Witte T. [Sjogren's syndrome]. *Dtsch Med Wochenschr*. 2016;141(8):544–50.
42. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. *Ann Rheum Dis*. 2017;76(1):9–16.
43. Chisholm DM, Mason DK. Labial salivary gland biopsy in Sjogren's disease. *J Clin Pathol*. 1968;21(5):656–60.
44. Daniels TE, Cox D, Shiboski CH, Schiodt M, Wu A, Lanfranchi H, et al. Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjogren's syndrome among 1,726 registry participants. *Arthritis Rheum*. 2011;63(7):2021–30.
45. Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dorner T, et al. Validation of EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). *Ann Rheum Dis*. 2015;74(5):859–66.
46. Ramos-Casals M, Brito-Zeron P, Bombardieri S, Bootsma H, De Vita S, Dorner T, et al. EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies. *Ann Rheum Dis*. 2020;79(1):3–18.
47. Cornec D, Saraux A, Jousse-Joulin S, Pers JO, Boisrame-Gastrin S, Renaudineau Y, et al. The Differential Diagnosis of Dry Eyes, Dry Mouth, and Parotidomegaly: A Comprehensive Review. *Clin Rev Allergy Immunol*. 2015;49(3):278–87.
48. Vivino FB, Bunya VY, Massaro-Giordano G, Johr CR, Giattino SL, Schorpion A, et al. Sjogren's syndrome: An update on disease pathogenesis, clinical manifestations and treatment. *Clin Immunol*. 2019;203:81–121.
49. Stone JH, Zen Y, Deshpande V. IgG4-related disease. *N Engl J Med*. 2012;366(6):539–51.
50. Vega Castro KP, Pertuz Charris NS. Diagnóstico diferencial dentro del espectro del síndrome de Sjögren. *Revista Colombiana de Reumatología*. 2020;27:67–74.
51. Leone MC, Alunno A, Cafaro G, Valentini V, Marcucci E, Bartoloni E, et al. The clinical spectrum of primary Sjogren's syndrome: beyond exocrine glands. *Reumatismo*. 2017;69(3):93–100.
52. Atzeni F, Sarzi-Puttini P, Lama N, Bonacci E, Bobbio-Pallavicini F, Montecucco C, et al. Anti-cyclic citrullinated peptide antibodies in primary Sjogren syndrome may be associated with non-erosive synovitis. *Arthritis Res Ther*. 2008;10(3):R51.
53. Berardicurti O, Marino A, Genovali I, Navarini L, D'Andrea S, Currado D, et al. Interstitial Lung Disease and Pulmonary Damage in Primary Sjogren's Syndrome: A Systematic Review and Meta-Analysis. *J Clin Med*. 2023;12(7).
54. Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH. Interstitial lung disease in primary Sjogren syndrome. *Chest*. 2006;130(5):1489–95.

55. Evans RD, Laing CM, Ciurtin C, Walsh SB. Tubulointerstitial nephritis in primary Sjogren syndrome: clinical manifestations and response to treatment. *BMC Musculoskelet Disord*. 2016;17:2.
56. Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. *Medicine (Baltimore)*. 2004;83(5):280–91.
57. Voulgarelis M, Moutsopoulos HM. Mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: risks, management, and prognosis. *Rheum Dis Clin North Am*. 2008;34(4):921–33, viii.
58. Tomiak C, Dorner T. [Sjogren's syndrome. Current aspects from a rheumatological point of view]. *Z Rheumatol*. 2006;65(6):505–17; quiz 18–9.
59. Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use. *Medicine (Baltimore)*. 2016;95(25):e3766.
60. Fox RI, Fox CM, McCoy SS. Emerging treatment for Sjogren's disease: a review of recent phase II and III trials. *Expert Opin Emerg Drugs*. 2023;28(2):107–20.
61. Jacobi C, Cursiefen C. [Ophthalmological complications in Sjogren's syndrome]. *Z Rheumatol*. 2010;69(1):32–40.
62. Hermann J, Horwath-Winter J. Diagnose und Therapie des Sjögren-Syndroms. *Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen*. 2019;26(2):50–6.
63. Stonecipher K, Perry HD, Gross RH, Kerney DL. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. *Curr Med Res Opin*. 2005;21(7):1057–63.
64. Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II Management and Therapy Report. *Ocul Surf*. 2017;15(3):575–628.
65. Talal N, Quinn JH, Daniels TE. The clinical effects of electrostimulation on salivary function of Sjogren's syndrome patients. A placebo controlled study. *Rheumatol Int*. 1992;12(2):43–5.
66. Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Bosch X, Tzioufas AG. Topical and systemic medications for the treatment of primary Sjogren's syndrome. *Nat Rev Rheumatol*. 2012;8(7):399–411.
67. Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X. Treatment of primary Sjogren syndrome: a systematic review. *JAMA*. 2010;304(4):452–60.
68. Valim V, Trevisani VF, Pasoto SG, Serrano EV, Ribeiro SL, Fidelix TS, et al. Recommendations for the treatment of Sjogren's syndrome. *Rev Bras Reumatol*. 2015;55(5):446–57.
69. Zehrfeld N, Witte T, Ernst D. Zielgerichtete Immuntherapien beim primären Sjögren-Syndrom. *Arthritis und Rheuma*. 2024;44(02):112–9.
70. Verstappen GM, van Nimwegen JF, Vissink A, Kroese FGM, Bootsma H. The value of rituximab treatment in primary Sjogren's syndrome. *Clin Immunol*. 2017;182:62–71.
71. Gueiros LA, France K, Posey R, Mays JW, Carey B, Sollecito TP, et al. World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjogren's syndrome: A systematic review. *Oral Dis*. 2019;25 Suppl 1(Suppl 1):102–10.
72. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puechal X, et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. *Ann Intern Med*. 2014;160(4):233–42.

73. Felten R, Scher F, Sibilia J, Gottenberg JE, Arnaud L. The pipeline of targeted therapies under clinical development for primary Sjogren's syndrome: A systematic review of trials. *Autoimmun Rev.* 2019;18(6):576–82.
74. Thorlacius GE, Björk A, Wahren-Herlenius M. Pos0820 Sex-Eqtl Analysis Reveals a Significant Sex-Bias in the Effects of Sjögren's Syndrome Associated Alleles on Gene Transcription. *Annals of the Rheumatic Diseases.* 2023;82.